PALI (Palisade Bio) EBIT per Share: $-1.07 (TTM As of Mar. 2026)


PALI Palisade Bio Inc PALI
35 GF Score
Price $2.11
! 2 Warning Signs
View Full Analysis

What is Palisade Bio EBIT per Share?

Palisade Bio PALI +6.60% 35 EBIT per Share is $-1.07 as of Mar. 2026. GuruFocus rates PALI with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 1,178 Biotechnology companies, Palisade Bio ranks better than 98.47% on this metric.

Palisade Bio's EBIT per Share for the three months ended in Mar. 2026 was $-0.05. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.07.

During the past 3 years, the average EBIT per Share Growth Rate was 89.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was 82.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Palisade Bio's EBIT per Share or its related term are showing as below:

PALI' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 77   Med: 77.9   Max: 89.2
Current: 89.2

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Palisade Bio was 89.20% per year. The lowest was 77.00% per year. And the median was 77.90% per year.

PALI's 3-Year EBIT Growth Rate is ranked better than
98.47% of 1178 companies
in the Biotechnology industry
Industry Median: 15.55 vs PALI: 89.20

Palisade Bio's EBIT for the three months ended in Mar. 2026 was $-9.60 Mil.

Palisade Bio  (NAS:PALI) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Palisade Bio EBIT per Share Related Terms

Palisade Bio EBIT per Share Historical Data

* Premium members only.

The historical data trend for Palisade Bio's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Palisade Bio EBIT per Share Chart

Palisade Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT per Share
Get a 7-Day Free Trial -2,018.17 -241.48 -26.94 -10.19 -0.30

Palisade Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.47 -0.58 -0.38 -0.06 -0.05
PALI
35GF Score
Palisade Bio Inc PALI
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Palisade Bio EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Palisade Bio's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-16.771/55.670
=-0.30

Palisade Bio's EBIT per Share for the quarter that ended in Mar. 2026 is calculated as

EBIT per Share(Q: Mar. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=-9.599/209.664
=-0.05

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-1.07 mean?
Palisade Bio (PALI) has a EBIT per Share of $-1.07 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Palisade Bio and its competitors. According to the industry distribution chart, Palisade Bio ranks #18 out of 1178 companies in the Biotechnology industry, placing it in the top 1.5%.
Is Palisade Bio's EBIT per Share too high?
Palisade Bio's current EBIT per Share is $-1.07. Based on the distribution chart, Palisade Bio ranks #18 out of 1178 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Palisade Bio has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Palisade Bio's EBIT per Share compare to IRD and GALT?
According to the Biotechnology industry distribution chart, Palisade Bio ranks #18 out of 1178 companies for EBIT per Share. This places Palisade Bio in the top 2% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,178 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Palisade Bio and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Palisade Bio's current EBIT per Share is $-1.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Palisade Bio stock overvalued right now?
Palisade Bio (PALI) has a current EBIT per Share of $-1.07. The current EBIT per Share is $-1.07. Palisade Bio's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Palisade Bio (PALI), the current EBIT per Share is $-1.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Palisade Bio Business Description

Address 4600 South Syracuse Street, Suite 900, Denver, CO, USA, 80237
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
35GF Score

Get the complete analysis for PALI

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.11
Price